Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

Onyx Health Targets Digital Growth with New Executive Director

Healthcare marketing communications agency Onyx Health have appointed Trevor Pill as their new Executive Director

Onyx Health

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

- PMLiVE

bluebird bio temporarily suspends trials of sickle cell gene therapy LentiGlobin

Company will also suspend marketing of beta-thalassemia gene therapy Zynteglo

- PMLiVE

BMS links up with Molecular Templates for oncology research collaboration

Deal could be worth up to $1.3bn in milestone payments

- PMLiVE

EU to begin new study programme investigating COVID-19 variants

Programme is expected to launch on Wednesday

- PMLiVE

Rare genetic diseases – what’s in store for 2021?

Why personalised medicine based on our own genomes is the future of healthcare

- PMLiVE

WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine

The emergency use listing authorises the use of the vaccine in all adults, including over-65s

- PMLiVE

US secures a further 100 million doses of Pfizer/BioNTech’s COVID-19 vaccine

US government will pay $1.95bn for additional 100 million doses

- PMLiVE

UK hits ‘significant milestone’ as 15 million people receive their first COVID-19 vaccine dose

The NHS also announced that five additional large-scale vaccination centres will open this week

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

- PMLiVE

Pfizer’s basic instincts

Business model evolution can’t defy strategic gravity

- PMLiVE

AZ/Oxford University’s COVID-19 vaccine to be evaluated in children and young adults

First study to assess the safety and immune response of the vaccine in children

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links